Does oral pancreatic enzyme replacement therapy improve appetite loss in patients with chronic heart failure?
Oral pancreatic enzyme replacement therapy may attenuate appetite loss in patients with chronic heart failure, highlighting a potential pancreatic-cardiac relationship.
Appetite loss is commonly seen in CHF, and is partially associated with pancreatic exocrine insufficiency. Oral pancreatic enzyme replacement therapy attenuates the chronic heart failure-induced appetite loss. These results suggest a possible pancreatic-cardiac relationship in chronic heart failure, and further experiment is needed for clarifying the possible mechanisms.
Xia et al. (Mon,) studied this question.